PJ34 (hydrochloride)
PJ34 hydrochloride is an inhibitor of PARP1/2 with IC50 of 110 nM and 86 nM, respectively.
Product Specifications
CAS Number
[344458-15-7]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
PARP
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/PJ34-hydrochloride.html
Purity
99.91
Solubility
DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 50 mg/mL (ultrasonic)
Smiles
O=C(NC(C=C1C2=C3C=CC=C2)=CC=C1NC3=O)CN(C)C.Cl
Molecular Formula
C17H18ClN3O2
Molecular Weight
331.80
Precautions
H302, H315, H319, H335
References & Citations
[1]Iwashita A, et al. A novel and potent poly (ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3- (4-phenyl-3,6-dihydro-1 (2H) -pyridinyl) propyl]-4 (3H) -quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia. J Ph|[2]Haddad M, et al. Anti-inflammatory effects of PJ34, a poly (ADP-ribose) polymerase inhibitor, in transient focal cerebral ischemia in mice. Br J Pharmacol. 2006 Sep;149 (1) :23-30.|[3]Diani-Moore S, et al. NAD+ loss, a new player in AhR biology: prevention of thymus atrophy and hepatosteatosis by NAD+ repletion. Sci Rep. 2017 May 23;7 (1) :2268.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PARP; PARP1; PARP2
Citation 01
Acta Biomater. 2022 Jul 15:147:327-341.|Anim Cells Syst. 2022 Aug 3;26 (4) :192-202.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Sci Rep. 2017 May 23;7 (1) :2268.|Antioxidants (Basel) . 2024 Apr 26, 13 (5), 525.|Antioxidants (Basel) . 2024 Apr 26;13 (5) :525.|Apoptosis. 2021 Dec;26 (11-12) :600-611.|Autophagy. 2025 May 8:1-24.|Biochim Biophys Acta Mol Basis Dis. 2024 Apr 22;1870 (5) :167190.|Bioorg Chem. 2024 Jun:147:107412.|bioRxiv. 2023 Oct 4.|bioRxiv. 2024 Sep 19:2024.09.19.613696.|bioRxiv. 2025 March 26.|Cancer Lett. 2021 Nov 1:520:26-37.|Cell Mol Life Sci. 2025 Oct 25;82 (1) :363.|Free Radic Biol Med. 2022 Feb 1:179:1-10.|J Enzyme Inhib Med Chem. 2025 Dec;40 (1) :2501743.|J Invest Dermatol. 2024 May 30:S0022-202X (24) 00384-1.|J Transl Med. 2024 Dec 27;22 (1) :1153.|J Virol. 2021 Jul 26;95 (16) :e0076021.|Mol Med Rep. 2024 Jun;29 (6) :102.|Nat Aging. 2024 May 9.|Norges teknisk-naturvitenskapelige universitet. 2024.|Norges teknisk-naturvitenskapelige universitet. 2025.|Nottingham Trent University. 2023 Sep 12.|Part Fibre Toxicol. 2020 Jun 8;17 (1) :23. |Patent. US20180263995A1.|Proc Natl Acad Sci U S A. 2023 Mar 28;120 (13) :e2213857120.|Regen Ther. 2023 Nov 10:24:592-601.|Research Square Print. 2022.|Sci Signal. 2023 Jan 17;16 (768) :eabh1083.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
